

Express Mail Label No.: EL862126348US  
Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 (CURA-120)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Spaderna *et al*  
ASSIGNEE: CuraGen Corporation  
SERIAL NUMBER: 09/735,981 EXAMINER: Not Yet Assigned  
FILING DATE: December 13, 2000 ART UNIT: 1653  
FOR: POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

TECH CENTER 1600/2900

SEP 05 2001

RECEIVED

Box IDS  
Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (2 pages);
- ☒ Modified Form 1449/PTO (2 pages) in duplicate; and,
- ☒ Return Postcard.

No fee is believed to be due at this time. However, the Commissioner is hereby authorized to charge any additional fees that may be due to Deposit Account No. 50-0311, Reference No. 15966-620 (CURA-120). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617/542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
Attorneys for Applicant  
MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

DATE: August 30, 2001

Express Mail Label No.: EL862126277US  
Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 CIP (Cura-120CIP)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Spaderna *et al.*

SERIAL NUMBER: 09/737,149

EXAMINER: Not Yet Assigned

FILING DATE: December 14, 2000

ART UNIT: 1646

FOR: POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

TECH CENTER 1600/2900

SEP 05 2001

RECEIVED

BOX IDS

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application.
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application.
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Spaderna *et al.*  
U.S.S.N.: 09/737,149

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 15966-620CIP (CURA-20CIP)

Respectfully submitted,



---

Ivor R. Elrifi, Reg. No. 39,529  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
Attorneys for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: August 30, 2001

Express Mail No. EL 862125277US  
Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 CIP (CURA-120CIP)

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/737,149
Filing Date	12/14/00
First Named Inventor	Spaderna et al
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	15966-620 CIP

### U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

### FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1*	WO 96/01640	Michigan Cancer Foundation	Jan. 25, 1995	
	B2*	WO 97/27747	Human Genome Sciences	Aug. 7, 1997	
	B3*	WO 97/35028	Human Genome Sciences	Sep. 25, 1997	
	B4*	WO 99/43696	AXYS Pharmaceuticals, Inc.	Sep. 2, 1999	

### OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1*	Adamson, P. B., E. Vanoli, et al. (1998). "Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction." <i>Cardiovasc Res</i> 40(1): 56-63.
	C2*	Doherty, et al., 1995 "Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein Phosphatase-1." <i>FEBS Lett.</i> 375 (3): 294-298. GenBank Accession Number: Y18208
	C3*	Doherty, et al., 1995 "Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein Phosphatase-1." <i>FEBS Lett.</i> 375 (3): 294-298. GenBank Accession Number: Q63759
	C4*	Doherty, M. J., J. Cadefau, et al. (1998). "Loss of the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient glycogen synthesis in insulin- dependent diabetic rats and in adrenalectomized starved rats." <i>Biochem J</i> 333(Pt 2): 253-7.
	C5*	Lamerdin, et al., 1998 "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster." Direct Submission. GenBank Accession Number: AC004528
	C6*	Lamerdin, et al., 1998 Direct Submission. GenBank Accession Number: O60391
	C7*	Lin, et al., 1996 "Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery." <i>Bran Res. Mol. Brain Res.</i> 43 (1-2): 57-64. GenBank Accession Number: Q14957
	C8*	Lloyd,D. 1999 Direct Submission. GenBank Accession Number: HS1163J1 (AL031588)
	C9*	Morris, G. F., R. Bullock, et al. (1999). "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators." <i>J Neurosurg</i> 91(5): 737-43.
	C10*	Muller, G. (2000). "Towards 3D structures of G protein-coupled receptors: a multidisciplinary approach." <i>Curr Med Chem</i> 7(9): 861-88.
	C11*	Nair, L. A. and A. O. Grant (1997). "Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential." <i>Cardiovasc Drugs Ther</i> 11(2): 149-67.
	C12*	Newman, T. 1998 Direct Submission. GenBank Accession Number: T14119
	C13*	Noorbala, et al., 1999 "Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia." <i>J Clin Pharm Ther</i> 24(5): 369-74.
	C14*	van Neuren, A. S., G. Muller, et al. (1999). "Molecular modelling studies on G protein-coupled receptors: from sequence to structure?" <i>J Recept Signal Transduct Res</i> 19(1-4): 341-53.

SEP 05 2001

RECEIVED

Express Mail No. EL 862126277US

Date of Deposit: August 30, 2001

Attorney Docket No. 15966-620 CIP (CURA-120CIP)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/735,981, filed December 13, 2000, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1560948v1

